Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.

This study is testing a drug called adbelimumab (an immunotherapy antibody) as an additional treatment given after surgery in people with esophageal squamous cell carcinoma (cancer of the food pipe) that has been surgically removed with clean margins. **You may be eligible if...** - You are 18 or older - You have esophageal squamous cell carcinoma at a specific stage (T1b-2 with node involvement, or T3-4a with or without node involvement) - You had surgery within the past 4–16 weeks and all cancer was removed (R0 resection) - Your heart and major organs are functioning well - Your performance status allows you to carry out daily activities **You may NOT be eligible if...** - Your cancer was initially deemed unresectable and you needed conversion therapy - You had severe complications after surgery - You have already started any type of adjuvant (post-surgery) therapy - You have active autoimmune disease (e.g., inflammatory bowel disease, hepatitis) - You have active hepatitis B or C, or HIV - You are pregnant or breastfeeding - You have significant uncontrolled heart disease Talk to your doctor to see if this trial is right for you.